Forum Agenda

July 24, 09:00 – 15:35

In-Vivo CAR-T and Cellular Therapy Session

Stay tuned

09:00-09:05
09:00-09:05 Opening Remarks    

 

09:05-09:20 Innovation and Progress of In Vivo CAR-T at Juventas Cell Therapy
Yi  Feng:CMO, Juventas Cell Therapy

 

09:20-09:35 iMagic In Vivo CAR-T – Ushering in a New Era of Cell Therapy
Crystal  Sun:Founder, Chairman & CEO, Immunofoco

 

09:35-09:50 mRNA-tLNP for in Vivo CAR-T: challenge and solution
Siyu Wang:Senior Scientist, Formulation Development, mRNA Division, Pengbo Biotechnology

 

09:50-10:05 "No Flow Cytometry Without ABclonal" – Comprehensive Flow Cytometry Solutions Empowering In Vivo CAR-T Drug Development
Zack Wu:Founder & CEO, ABclonal

 

10:05-10:20 Break

 

10:20-10:35 Recombinant Antibody-Based Flow Cytometry Analysis and Novel Strategies for CAR-T Detection Reagents

Yanan Lu:Director of Recombinant Antibody R&D Department, Proteintech

 

10:35-10:50 Conjugation Technology-Driven Evolution of In Vivo CAR-T: From Precision Targeting to Regulatory Readiness
James Fang:Founder & CEO, Enorna Biotechnology

 

10:50-11:05 The Road to In Vivo CAR-T Success: Progress, Challenges, Strategies, and Clinical Translation
Xiaowen He:Co-founder & Chief Scientific Officer, Origincell Therapeutics

 

11:05-11:20 From Origin to Endpoint: Building the 'Highway' for In Vivo CAR-T Preclinical Research
Fei Tian:R&D Director, MileCell

 

11:20-11:35 Viral Vectors for In Vivo Gene Delivery: Design, Process Development and Critical Quality Control
Ming-Wei Che:RephImmune Founder & CEO

 

11:35-11:50 In Vivo CAR-T Gene Delivery Technology Routes and Key Process Development Considerations
Ping Zou:Vice President & Head of Technical Team, WuXi ATU

 

11:50-12:05 Innovation and Progress of In Vivo CAR-T at IASO Biotherapeutics
Min Zhang:Head of Global Business Development, IASO Biotherapeutics

 

12:05-12:20 Source Compliance: An Integrated Bioprocessing Platform Empowering In Vivo CAR-T Drug Discovery and Manufacturing
Mars Wang:Director of Product Business Development, Lepure Biotech

 

12:20-13:30 Lunch Break

 

13:30-13:50 Proprietary LNP Delivery Technology and In Vivo CAR-T
Siyuan Yin:COO,TheMedium Therapeutics

 

13:50-14:05 Process Synergies in Cell Therapy: Breakthroughs and Perspectives on In Vivo vs. Ex Vivo Approaches
Lei Xu:Project Lead, Genechem

 

14:05-14:20 Ab-LNP One-Stop Characterization Services to Accelerate the Industrialization of In Vivo CAR-T
Xingxing Wang:Vice General Manager, Oligonucleotide Business Unit, Synthgene

 

14:20-14:35 Development Progress of In Vivo TCR-T Therapies Targeting Hepatitis B Virus

Xiaoming Peng:CEO, Lion TCR

 

14:35-14:50 Next-Generation Humanized Models Empowering In Vivo Cell Therapy: A Focus on Efficacy and Safety Assessment

Xinxin Zhang:Head of Preclinical Innovation & Services, genOway Shanghai

 

14:50-15:05 In Vivo CAR-Tumor: A Game-Changer in Immuno-Oncology
George Zhou:CEO, Joint Biosciences 

 

15:05-15:20 Toward immune reset: early clinical evidence of allo CAR-T in autoimmune disease
Wengang Ge:VP Clinical Development, Imviva Biotechnologies

 

15:20-15:35王文新Wenxin  Wang聚茵生物创始人、CSO;都柏林大学/安徽理工大学 讲席教授Founder&CSO, PolyGene Biotech;Chair Professor at University College Dublin / Anhui University of Science and Technology
15:20-15:35 Advanced Technology for Better In Vivo CAR-T: Breakthroughs in Lentiviral Vector Production and HPAE Polymer-Based Delivery Systems

Wenxin  Wang:Founder&CSO, PolyGene Biotech;Chair Professor at University College Dublin / Anhui University of Science and Technology